Cell & Gene Therapy
Cell & Gene Supply Chain
From clinical to commercial, only Marken can seamlessly guide your cell and gene therapies through each stage of the biopharmaceutical logistics journey from vein-to-vein. To ensure cell and gene therapies are brought to market successfully, pharma and biotech companies must address logistical complexities within the clinical supply chain, which requires specialized solutions, industry-leading expertise and a rigorous control process coupled with advanced technology.
Marken’s unique cell and gene supply chain services feature industry-defining expertise consisting of specialized teams of biopharma industry and logistics specialists.
In addition, we provide direction on shifting regulatory and trade compliance guidelines and offer high-touch oversight from operations, project management, control tower, and quality teams. Explore more about our cell and gene services below.
Related resources
Marken’s 24/7 Cell & Gene Control Tower Provides Agile Solution for Critical Shipments
9 February 2023
Marken’s Cell and Gene Control Tower re-routed six critical shipments of CAR-T drug products from Amsterdam to the UK and…
Operational Excellence Overcomes Obstacles to Deliver Critical Autologous Cell Therapy
9 February 2023
Marken utilized operational excellence to deliver a critical autologous cell therapy. Although there were many challenges, Marken was able to…
Marken Successfully Safeguards the Viability of Pharmaceutical Samples Within 42 Hours
4 January 2023
The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery…
Happy Holidays from Marken
21 December 2022
At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…
Marken Overcomes Multiple Obstacles To Successfully Deliver Critical Stem Cell Samples Across The Globe
9 December 2022
Stem cell samples require extremely tight 24-hour turnaround times in order to be modified and processed for critical cell therapy…
Personalized Medicine Requires Complex Supply Chains: Marken
26 July 2021
Outsourcing-Pharma and Nina Vas, Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, discuss the specific requirements involved…
Evaluating a Clinical Supply Chain Partner to Meet Your Vaccine Trial Needs
23 April 2021
It is essential for pharmaceutical companies to evaluate many factors when choosing a clinical supply chain partner. With today’s global…
Decentralized Trials Call for Supply Chain Flexibility: Marken
8 April 2021
Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…
Marken Successfully Ensures On-Time Release Of CAR-T Cell Treatment In Spain
18 March 2021
Overcoming Brexit challenges to coordinate time-sensitive shipments About Marken Marken is a wholly owned subsidiary of UPS and is a…
Marken Makes It Happen COVID-19
13 October 2020
In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The Marken team is…
Solving Complexities In the Era Of Personalized Medicine
14 October 2019
Cell and gene therapies are fundamentally different than traditional medicines, from the patient and product journeys to the systems and…
Cell and Gene Therapies: The Next Frontier in Medicine
3 May 2019
Cell and gene therapies are the future of healthcare and the logistics for these complex therapies are disrupting the traditional…
Delivering What Matters
Experience the capabilities of three UPS companies uniting as one. Together, we are Marken UPS Healthcare Precision Logistics.
Login and quick links